BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther 2016; 7(1): 33-40 [PMID: 26855810 DOI: 10.4292/wjgpt.v7.i1.33] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;51:34-52. [DOI: 10.1111/apt.15598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
2 Taaffe J, Wilson D. Mobilising a global response to hepatitis: Lessons learned from the HIV movement. Glob Public Health 2018;13:473-88. [PMID: 27748158 DOI: 10.1080/17441692.2016.1233989] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Cevik O, Li D, Baljinnyam E, Manvar D, Pimenta EM, Waris G, Barnes BJ, Kaushik-Basu N. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. J Biol Chem 2017;292:21676-89. [PMID: 29079574 DOI: 10.1074/jbc.M117.792721] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
4 Warzyszyńska K, Jonas M, Wasiak D, Kosieradzki M, Małkowski P. Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment - preliminary report. Clin Exp Hepatol 2017;3:194-7. [PMID: 29255807 DOI: 10.5114/ceh.2017.71483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
5 Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther 2016;5:491-508. [PMID: 27783223 DOI: 10.1007/s40121-016-0134-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
6 Matsumoto K, Miyaaki H, Fukushima M, Sasaki R, Haraguchi M, Miuma S, Nakao K. The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection. Biomed Rep 2022;16:9. [PMID: 34987793 DOI: 10.3892/br.2021.1492] [Reference Citation Analysis]
7 Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. J Hepatocell Carcinoma 2020;7:347-60. [PMID: 33299823 DOI: 10.2147/JHC.S279657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Huynh T, Zhang J, Hu KQ. Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. J Clin Transl Hepatol 2018;6:258-63. [PMID: 30271737 DOI: 10.14218/JCTH.2018.00014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lo Menzo S, Biagi E, Di Nuzzo M, Grilli A, Contini C. SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient. Ann Hepatol 2018;17:661-4. [PMID: 29893709 DOI: 10.5604/01.3001.0012.0950] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Morales-Arraez D, Hernandez-Guerra M, Diaz-Flores F, Nieto-Bujalance Y, Garcia-Dopico J, Jimenez A, Quintero E. Hepatitis C virus media coverage favorably impacts on antibody testing in the non-interferon era. J Public Health (Oxf) 2021;43:385-91. [PMID: 31786606 DOI: 10.1093/pubmed/fdz149] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Moreno-Cubero E, Larrubia JR. Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol 2016; 22(28): 6469-6483 [PMID: 27605882 DOI: 10.3748/wjg.v22.i28.6469] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
12 Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. AIDS Care 2019;31:1340-7. [PMID: 30829533 DOI: 10.1080/09540121.2019.1587353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Page SJ, Rivera MM, Kleiner DE, Zhao X, Auh S, Remmers EF, Heller T. Three variants in the nicotinamide adenine dinucleotide phosphate oxidase complex are associated with HCV-related liver damage. Hepatol Commun 2017;1:973-82. [PMID: 29404504 DOI: 10.1002/hep4.1103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Makhlouf NA, Farouk M, Nafeh HM, Hasanain AFA, El-mokhtar MA, Hetta HF, Mekky MA, Alboraie M, Elamin H, Nasr AM. NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00080-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Gummow J, Masavuli MG, Mekonnen ZA, Li Y, Wijesundara DK, Shrestha AC, Voskoboinik I, Gowans EJ, Grubor-Bauk B. Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus. Vaccines (Basel) 2020;8:E53. [PMID: 32013228 DOI: 10.3390/vaccines8010053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]